Ranolazine

Chemical formula: C₂₄H₃₃N₃O₄  Molecular mass: 427.537 g/mol  PubChem compound: 56959

Therapeutic indications

Ranolazine is indicated for:

Stable angina pectoris

Population group: only adults (18 years old or older)

Ranolazine is indicated in adults as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies (such as beta-blockers and/or calcium antagonists).

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Ranolazine is contraindicated in the following cases:

Severe renal impairment (creatinine clearance <30 ml/min)

at least one of

Renal failure stage 5: Kidney failure (GFR <15 mL/min/1.73 m2 or dialysis)

Moderate or severe hepatic impairment

at least one of
Hepatic failure stage III
Hepatic failure stage IV

Potent CYP3A4 inhibitors

Strong CYP3A4 inhibitors

Class Ia antiarrhythmics

Antiarrhythmics, class Ia

Class III antiarrhythmics other than amiodarone

at least one of
Bretylium
Bunaftine
Dofetilide
Ibutilide
TEDISAMIL
Dronedarone

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2019: RANEXA Prolonged-release tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈